Renaissance Technologies LLC Has $838,000 Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

Renaissance Technologies LLC lifted its holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) by 8.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 187,839 shares of the company’s stock after purchasing an additional 14,139 shares during the quarter. Renaissance Technologies LLC owned about 0.30% of Inozyme Pharma worth $838,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Meeder Asset Management Inc. bought a new position in Inozyme Pharma in the second quarter valued at approximately $68,000. Values First Advisors Inc. bought a new stake in Inozyme Pharma in the 2nd quarter valued at $76,000. American Century Companies Inc. boosted its stake in Inozyme Pharma by 11.0% in the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after purchasing an additional 5,673 shares during the period. Rhumbline Advisers boosted its stake in Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares during the period. Finally, Superstring Capital Management LP bought a new position in Inozyme Pharma during the 4th quarter worth about $528,000. 88.30% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on INZY. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Wedbush reaffirmed an “outperform” rating and set a $15.00 price target on shares of Inozyme Pharma in a research report on Monday, September 30th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Inozyme Pharma in a report on Thursday, August 8th. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $16.14.

Inozyme Pharma Trading Up 1.0 %

NASDAQ INZY opened at $5.22 on Tuesday. Inozyme Pharma, Inc. has a 12 month low of $2.69 and a 12 month high of $7.80. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48. The stock has a 50 day moving average of $5.19 and a 200-day moving average of $5.10. The company has a market cap of $322.89 million, a PE ratio of -3.81 and a beta of 1.51.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). On average, equities research analysts anticipate that Inozyme Pharma, Inc. will post -1.68 EPS for the current fiscal year.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.